Last reviewed · How we verify
Intradermal influenza vaccine
An intradermal influenza vaccine that delivers the vaccine antigen into the dermis to enhance immune response through activation of skin-resident immune cells.
An intradermal influenza vaccine that delivers the vaccine antigen into the dermis to enhance immune response through activation of skin-resident immune cells. Used for Influenza prevention in adults.
At a glance
| Generic name | Intradermal influenza vaccine |
|---|---|
| Sponsor | The University of Hong Kong |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Intradermal administration targets the dermis layer of skin, which is rich in dendritic cells and other antigen-presenting cells, potentially generating stronger and broader cellular and humoral immune responses compared to intramuscular vaccination. This route may improve immunogenicity and potentially reduce the antigen dose required while maintaining or enhancing protective efficacy against influenza infection.
Approved indications
- Influenza prevention in adults
Common side effects
- Injection site erythema
- Injection site induration
- Injection site pruritus
- Myalgia
- Fatigue
Key clinical trials
- Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (PHASE1)
- Intradermal Influenza Vaccination (EARLY_PHASE1)
- Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand (PHASE4)
- Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children (PHASE1, PHASE2)
- H7HLAII DNA Influenza Vaccine (PHASE1)
- Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years (PHASE1)
- Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients (PHASE3)
- Safety of 4Fluart ID Suspension for Injection in Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intradermal influenza vaccine CI brief — competitive landscape report
- Intradermal influenza vaccine updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI